slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,011-65,040
Pages 2,605
Rows per page 30
Component
65,011-65,040 of 78,138
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Includes visual longitudinal data (photos) and quantitative bar chart data.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
29
The slide uses a Gantt-style timeline to show the duration of IP protection and exclusivity for various therapeutic assets.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
06
The chart uses a Marimekko-style layout to show segment size and growth.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
10
The chart displays capital allocation trends over time, with a specific callout for Q1 FY24.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
14
The chart illustrates the deduction of various operating expenses from revenue to arrive at adjusted operating income.Factset | Results Presentation Deck | 22 slides · FactSet
Conference presentation Investor relations 1 hit
03
Includes four pie charts showing market segmentation and five big-number metrics at the bottom.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Product1 hit
12
The slide uses a combination of a bar chart for historical data and an arrow-based visual to represent future growth drivers.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Solution1 hit
14
FGI Industries | Investor Presentation Deck | 30 slidesFGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
14
Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
17
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
14
The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
17
The slide uses a visual timeline comparison to highlight the clinical advantage of NXC-201's shorter side-effect profile.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
21
The slide uses a bar chart to compare hematologic and cardiac response rates across different therapies.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
23
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
29
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
30
The slide uses a stylized area chart to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
35
The chart illustrates clinical trial efficacy data for NXC-201.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
46
The slide uses a bar chart to contrast the combined market size of two groups of drugs ($33.4bn vs $0.9bn).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit